03:35 , Jun 16, 2018 |  BioCentury  |  Product Development

MATCH’s long game

Although three of the first four arms in NCI-MATCH missed their endpoints, the results suggest the basket trial is doing what it is supposed to -- finding efficacy signals in rare cancers. It’s also yielded...
14:11 , May 18, 2018 |  BC Week In Review  |  Clinical News

NCI-MATCH arms fall short in ASCO abstracts

Three arms of NCI’s Molecular Analysis for Therapy Choice (NCI-MATCH) tissue agnostic basket trial will report overall response rates (ORR) below 10% at the American Society of Clinical Oncology (ASCO) meeting in Chicago, according to...
21:04 , May 16, 2018 |  BC Extra  |  Clinical News

NCI-MATCH arms fall short in ASCO abstracts

Three arms of NCI’s Molecular Analysis for Therapy Choice (NCI-MATCH) tissue agnostic basket trial will report overall response rates below 10% at this year’s American Society of Clinical Oncology meeting, according to abstracts released late...
23:30 , Mar 13, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of PHLDA1 could help predict resistance to RTK inhibitors in endometrial, breast and other cancers. In tumor samples from patients with metastatic breast cancer or locally advanced non-metastatic renal cancer...
07:00 , Sep 5, 2016 |  BioCentury  |  Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
07:00 , Jul 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fibroblast growth factor receptor 1 (FGFR1; CD331); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); K-Ras (KRAS)

Cancer INDICATION: Lung cancer; pancreatic cancer Studies in cell culture and mice suggest combining FGFR1 inhibitors with the MEK1 / MEK2 inhibitor Mekinist trametinib could help treat KRAS-mutant lung and pancreatic cancers. In KRAS-mutant human...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Opdivo nivolumab: Phase II/III amended

The Phase II/III Lung-MAP (S1400) lung cancer study added an arm that tests Opdivo nivolumab alone or in combination with Yervoy ipilimumab in patients with squamous cell lung cancer who do not have a biomarker...
02:42 , Mar 2, 2016 |  BC Extra  |  Clinical News

Lung-MAP adds non-biomarker Opdivo arm

The Phase II/III Lung-MAP (S1400) lung cancer study now includes an arm that tests PD-1 inhibitor Opdivo nivolumab alone or in combination with Yervoy ipilimumab in patients who do not have a biomarker that matches...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

AZD4547: Phase II data

An open-label, U.K. Phase II trial in patients with fibroblast growth factor (FGF) receptor 1 ( FGFR1 ; CD331 )- or FGFR2-amplified tumors showed that twice-daily 80 mg oral AZD4547 for the first 2 weeks...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

AZD4547: Phase II data

The open-label, international Phase II SHINE trial in 71 patients with previously treated advanced gastric cancer with FGFR2 polysomy or gene amplification showed that twice-daily 80 mg oral AZD4547 for the first 2 weeks of...